TG Therapeutics (TGTX) Guidance Raise Puts Its Valuation Story Back In Focus

Simply Wall St.11-13

Why TG Therapeutics Stock Is Back in Focus TG Therapeutics (TGTX) moved back onto investor radars after management lifted full year 2026 revenue guidance to about US$1b and reported detailed third ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment